MA34516B1 - Imidizopyridazines substituees - Google Patents

Imidizopyridazines substituees

Info

Publication number
MA34516B1
MA34516B1 MA35720A MA35720A MA34516B1 MA 34516 B1 MA34516 B1 MA 34516B1 MA 35720 A MA35720 A MA 35720A MA 35720 A MA35720 A MA 35720A MA 34516 B1 MA34516 B1 MA 34516B1
Authority
MA
Morocco
Prior art keywords
compounds
imidizopyridazines
substituted
formula
ttk
Prior art date
Application number
MA35720A
Other languages
English (en)
Inventor
Ulrich Klar
Marcus Koppitz
Rolf Jautelat
Dirk Kosemund
Rolf Bohlmann
Philip Lienau
Gerhard Siemeister
Antje Margret Wengner
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of MA34516B1 publication Critical patent/MA34516B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Paper (AREA)

Abstract

)CETTE INVENTION CONCERNE DES COMPOSÉS D'IMIDAZOPYRIDAZINES SUBSTITUÉES DE FORMULE GÉNÉRALE (1), QUI SONT DES INHIBITEURS DE MPS-1 (FUSEAU MONOPOLAIRE 1) (ÉGALEMENT CONNU SOUS LE NOM DE TYROSINE THRÉONINE KINASE, TTK), R3, R5, ET A DANS LA FORMULE (1) ÉTANT TELS QUE DÉFINIS DANS LES REVENDICATIONS, AINSI QUE DES PROCÉDÉS DE PRÉPARATION DESDITS COMPOSÉS, DES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT ET L'UTILISATION DESDITS COMPOSÉS POUR FABRIQUER UNE COMPOSITION PHARMACEUTIQUE DESTINÉE À TRAITER OU À PRÉVENIR UNE MALADIE, EN PARTICULIER, UN TROUBLE HYPER-PROLIFÉRATIF ET/OU DE TYPE ANGIOGENÈSE, À TITRE D'AGENT UTILISÉ SEUL OU EN ASSOCIATION AVEC D'AUTRES PRINCIPES ACTIFS.
MA35720A 2010-09-10 2011-09-06 Imidizopyridazines substituees MA34516B1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP10176134 2010-09-10
EP11075022 2011-02-04
EP11170771 2011-06-21
EP11170775 2011-06-21
PCT/EP2011/065368 WO2012032031A1 (fr) 2010-09-10 2011-09-06 Imidazopyridazines substituées

Publications (1)

Publication Number Publication Date
MA34516B1 true MA34516B1 (fr) 2013-09-02

Family

ID=44545741

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35720A MA34516B1 (fr) 2010-09-10 2011-09-06 Imidizopyridazines substituees

Country Status (38)

Country Link
US (1) US9255100B2 (fr)
EP (1) EP2614063B1 (fr)
JP (1) JP5824050B2 (fr)
KR (1) KR20140032337A (fr)
CN (1) CN103370318B (fr)
AP (1) AP3607A (fr)
AR (1) AR082946A1 (fr)
AU (1) AU2011298844B2 (fr)
BR (1) BR112013005679A2 (fr)
CA (1) CA2810755A1 (fr)
CO (1) CO6720961A2 (fr)
CR (1) CR20130102A (fr)
CU (1) CU24187B1 (fr)
CY (1) CY1117352T1 (fr)
DK (1) DK2614063T3 (fr)
DO (1) DOP2013000054A (fr)
EA (1) EA023420B1 (fr)
EC (1) ECSP13012752A (fr)
ES (1) ES2568220T3 (fr)
HR (1) HRP20160360T1 (fr)
HU (1) HUE028771T2 (fr)
IL (1) IL225058A (fr)
MA (1) MA34516B1 (fr)
ME (1) ME02389B (fr)
MX (1) MX2013002713A (fr)
MY (1) MY185139A (fr)
NZ (1) NZ607904A (fr)
PE (1) PE20131164A1 (fr)
PH (1) PH12013500454A1 (fr)
PL (1) PL2614063T3 (fr)
RS (1) RS54661B1 (fr)
SA (1) SA111320735B1 (fr)
SG (1) SG188417A1 (fr)
SI (1) SI2614063T1 (fr)
TW (1) TWI541243B (fr)
UY (1) UY33598A (fr)
WO (1) WO2012032031A1 (fr)
ZA (1) ZA201301756B (fr)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI541243B (zh) 2010-09-10 2016-07-11 拜耳知識產權公司 經取代咪唑并嗒
WO2012088266A2 (fr) 2010-12-22 2012-06-28 Incyte Corporation Imidazopyridazines et benzimidazoles substitués en tant qu'inhibiteurs de fgfr3
DK2734205T3 (en) * 2011-07-21 2018-06-14 Tolero Pharmaceuticals Inc Heterocyclic Protein Kinase Inhibitors
JP6166289B2 (ja) * 2012-03-14 2017-07-19 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 置換イミダゾピリダジン
CA2876689C (fr) 2012-06-13 2022-04-26 Incyte Corporation Composes tricycliques substitues utilises comme inhibiteurs de fgfr
WO2014020043A1 (fr) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinaisons pour le traitement du cancer
WO2014020041A1 (fr) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinaisons pour le traitement du cancer
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
EP2920181B1 (fr) 2012-11-16 2019-01-09 University Health Network Composés de pyrazolopyrimidine
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
TW201437211A (zh) * 2013-03-01 2014-10-01 Bayer Pharma AG 經取代咪唑并嗒□
PH12015502383B1 (en) 2013-04-19 2023-02-03 Incyte Holdings Corp Bicyclic heterocycles as fgfr inhibitors
CA2914745A1 (fr) 2013-06-11 2014-12-18 Bayer Pharma Aktiengesellschaft Derives de type promedicament de triazolopyridines substituees
AP2015008915A0 (en) * 2013-06-13 2015-12-31 Bayer Pharma AG Combination of a imidazopyridazine derivative and a mitotic agent for the treatment of cancer
CN103360399B (zh) * 2013-08-02 2016-03-02 北京大学 6-芳基取代-咪唑-[1,2-b]哒嗪类衍生物，其制备方法及用途
GB201321734D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
BR112016019161B1 (pt) * 2014-02-21 2022-12-20 Frost Biologic, Inc Amidas antimitóticas, composições farmacêuticas que as compreendem e uso das mesmas
WO2015157955A1 (fr) 2014-04-17 2015-10-22 Abbvie Inc. Inhibiteurs de tyrosine kinase de bruton (btk) hétérocyclique
TW201613927A (en) * 2014-09-01 2016-04-16 Bayer Pharma AG Method for preparation of substituted imidazopyridazines
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
CA2976790C (fr) 2015-02-20 2024-02-27 Incyte Corporation Heterocycles bicycliques utilises en tant qu'inhibiteurs de fgfr
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
EP3283642B1 (fr) 2015-04-17 2023-10-11 Netherlands Translational Research Center Holding B.V. Biomarqueurs pronostiques pour chimiothérapie basée sur un inhibiteur de ttk
WO2016187028A1 (fr) * 2015-05-15 2016-11-24 Celgene Avilomics Research, Inc. Composés hétéroaryles, leur synthèse, et intermédiaires de ceux-ci
US10252918B2 (en) * 2015-12-04 2019-04-09 Exxonmobil Research And Engineering Company EMM-28, a novel synthetic crystalline material, its preparation and use
US11352328B2 (en) 2016-07-12 2022-06-07 Arisan Therapeutics Inc. Heterocyclic compounds for the treatment of arenavirus
CN109476667B (zh) * 2016-07-18 2022-06-28 大学健康网络 Ttk抑制剂的固体形式
ES2901421T3 (es) * 2017-04-11 2022-03-22 Straumann Holding Ag Implante dental
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
RS66310B1 (sr) 2018-05-04 2025-01-31 Incyte Corp Čvrsti oblici inhibitora fgfr i procesi za njegovu pripremu
KR102956194B1 (ko) 2018-05-04 2026-04-23 인사이트 코포레이션 Fgfr 억제제의 염
MY202833A (en) 2018-05-08 2024-05-24 Nippon Shinyaku Co Ltd Azabenzimidazole compounds and pharmaceutical
US12419865B2 (en) 2018-12-06 2025-09-23 Arisan Therapeutics Inc. Compounds for the treatment of arenavirus infection
HUE072069T2 (hu) 2019-02-12 2025-10-28 Sumitomo Pharma America Inc 2-((1R,4R)-4-((3-(3-(trifluormetil)fenil)imidazo[1,2- b]piridazin-6-il)amino)ciklohexil)propán-2-ol sósavas sójának kristályos formája
WO2020185532A1 (fr) 2019-03-08 2020-09-17 Incyte Corporation Méthodes de traitement du cancer au moyen d'un inhibiteur de fgfr
CN111978325B (zh) * 2019-05-22 2023-11-17 中国药科大学 咪唑并哒嗪类mnk1/mnk2激酶抑制剂及其制备方法和应用
WO2021007269A1 (fr) 2019-07-09 2021-01-14 Incyte Corporation Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
GEP20247679B (en) 2019-10-14 2024-10-10 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CA3161582A1 (fr) 2019-11-13 2021-05-20 Nippon Shinyaku Co., Ltd. Compose azabenzimidazole et medicament
MX2022006691A (es) 2019-12-04 2022-09-19 Incyte Corp Derivados de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr).
WO2021113479A1 (fr) 2019-12-04 2021-06-10 Incyte Corporation Hétérocycles tricycliques en tant qu'inhibiteurs de fgfr
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
EP4323405A1 (fr) 2021-04-12 2024-02-21 Incyte Corporation Polythérapie comprenant un inhibiteur de fgfr et un agent de ciblage de nectine-4
CA3220274A1 (fr) 2021-06-09 2022-12-15 Incyte Corporation Heterocycles tricycliques en tant qu'inhibiteurs de fgfr
TW202313610A (zh) 2021-06-09 2023-04-01 美商英塞特公司 作為ｆｇｆｒ抑制劑之三環雜環
MX2024007450A (es) * 2021-12-15 2024-07-04 Sillajen Inc Combinaciones farmaceuticas para utilizarse en el tratamiento de enfermedades neoplasicas.
WO2024155842A1 (fr) * 2023-01-19 2024-07-25 Skyhawk Therapeutics, Inc. Compositions utiles pour moduler l'épissage

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL332040A1 (en) 1996-08-28 1999-08-16 Pfizer Substitution 6,5-heterobicyclic derivatives
EP1277754B8 (fr) 2000-04-27 2005-09-28 Astellas Pharma Inc. Derives d'imidazopyridine
KR20060056944A (ko) 2003-07-14 2006-05-25 아레나 파마슈티칼스, 인크. 대사 조절제로서 융합된 아릴 및 헤테로아릴 유도체 및이에 관련된 장애의 예방 또는 치료
CA2555263A1 (fr) 2004-02-12 2005-09-01 Neurogen Corporation Imidazo-pyridazines, triazolo-pyridazines et ligands associes des recepteurs de benzodiazepine
US7306631B2 (en) 2004-03-30 2007-12-11 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
US20070049591A1 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Inhibitors of MAPK/Erk Kinase
US20070078136A1 (en) * 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US7723336B2 (en) 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
EP1945644A2 (fr) * 2005-11-10 2008-07-23 Schering Corporation Imidazopyrazines inhibant la proteine kinase
TW200840584A (en) * 2006-12-26 2008-10-16 Gilead Sciences Inc Pyrido(3,2-d)pyrimidines useful for treating viral infections
US8546394B2 (en) * 2007-04-17 2013-10-01 Bristol-Myers Squibb Company Substituted [1,2,4]triazolo[4,3-A]pyrazine 11-beta-hydroxysteroid dehydrogenase inhibitors
US20110046127A1 (en) 2007-11-08 2011-02-24 Paolo Pevarello Imidazopyridazines for Use as Protein Kinase Inhibitors
WO2009100375A1 (fr) 2008-02-06 2009-08-13 Bristol-Myers Squibb Company Imidazopyridazines substituées utiles en tant qu’inhibiteurs de kinase
TWI491610B (zh) 2008-10-09 2015-07-11 必治妥美雅史谷比公司 作為激酶抑制劑之咪唑并嗒腈
WO2010088518A2 (fr) 2009-01-31 2010-08-05 Kalypsys, Inc. Modulateurs hétérocycliques du gpr119 pour le traitement de maladies
JP6168773B2 (ja) * 2009-04-29 2017-07-26 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 置換イミダゾキノキサリン
TW201107329A (en) * 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
WO2011026579A1 (fr) 2009-09-04 2011-03-10 Bayer Schering Pharma Aktiengesellschaft Aminoquinoxalines substituées servant d'inhibiteurs de tyrosine-thréonine kinases
EP2343297A1 (fr) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
EP2343294A1 (fr) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines substituées
EP2343295A1 (fr) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Dérivés de triazolopyridine
ES2551407T3 (es) 2010-03-18 2015-11-18 Bayer Intellectual Property Gmbh Imidazopirazinas
CN103038235B (zh) 2010-06-01 2015-07-29 拜耳知识产权有限责任公司 取代的咪唑并吡嗪
TWI541243B (zh) 2010-09-10 2016-07-11 拜耳知識產權公司 經取代咪唑并嗒
US9284317B2 (en) 2010-12-17 2016-03-15 Bayer Intellectual Property Gmbh Substituted imidazo[1,2-a]pyrazines as MPS-1 inhibitors
CA2821829A1 (fr) 2010-12-17 2012-06-21 Bayer Intellectual Property Gmbh Imidazopyrazines pour l'utilisation en tant qu'inhibiteurs de mps-1 et de tkk dans le traitement de troubles d'hyperproliferation
WO2012080232A1 (fr) 2010-12-17 2012-06-21 Bayer Pharma Aktiengesellschaft Imidazopyrazines 2-substituées pour l'utilisation en tant qu'inhibiteurs de mps-1 et de tkk dans le traitement de troubles d'hyperprolifération
US20140187548A1 (en) 2010-12-17 2014-07-03 Bayer Intellectual Property Gmbh 6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
WO2012080228A1 (fr) 2010-12-17 2012-06-21 Bayer Pharma Aktiengesellschaft Imidazopyrazines 6-thio substituées pour l'utilisation en tant qu'inhibiteurs de mps-1 et de tkk dans le traitement de troubles d'hyperprolifération
US20140135319A1 (en) 2010-12-17 2014-05-15 Bayer Intellectual Property Gmbh 6-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders

Also Published As

Publication number Publication date
SG188417A1 (en) 2013-04-30
AP2013006790A0 (en) 2013-04-30
ZA201301756B (en) 2016-06-29
EA201390339A1 (ru) 2013-09-30
PH12013500454A1 (en) 2013-04-29
DK2614063T3 (en) 2016-04-18
AU2011298844A1 (en) 2013-03-28
HRP20160360T1 (hr) 2016-05-06
NZ607904A (en) 2015-02-27
AU2011298844B2 (en) 2015-02-19
CY1117352T1 (el) 2017-04-26
KR20140032337A (ko) 2014-03-14
CU20130033A7 (es) 2013-08-29
ME02389B (fr) 2016-09-20
EP2614063A1 (fr) 2013-07-17
CN103370318A (zh) 2013-10-23
ECSP13012752A (es) 2014-01-31
EP2614063B1 (fr) 2016-01-13
CU24187B1 (es) 2016-07-29
AR082946A1 (es) 2013-01-23
UY33598A (es) 2012-04-30
HUE028771T2 (en) 2016-12-28
WO2012032031A1 (fr) 2012-03-15
DOP2013000054A (es) 2013-07-31
CO6720961A2 (es) 2013-07-31
IL225058A (en) 2017-03-30
ES2568220T3 (es) 2016-04-28
PL2614063T3 (pl) 2016-06-30
US20130338133A1 (en) 2013-12-19
RS54661B1 (sr) 2016-08-31
TWI541243B (zh) 2016-07-11
HK1187623A1 (zh) 2014-04-11
SA111320735B1 (ar) 2015-10-21
MX2013002713A (es) 2013-05-22
JP5824050B2 (ja) 2015-11-25
EA023420B1 (ru) 2016-06-30
US9255100B2 (en) 2016-02-09
TW201211049A (en) 2012-03-16
BR112013005679A2 (pt) 2016-05-03
PE20131164A1 (es) 2013-10-30
CN103370318B (zh) 2016-04-20
CR20130102A (es) 2013-04-17
MY185139A (en) 2021-04-30
AP3607A (en) 2016-02-26
SI2614063T1 (sl) 2016-05-31
JP2013537174A (ja) 2013-09-30
CA2810755A1 (fr) 2012-03-15

Similar Documents

Publication Publication Date Title
MA52492B1 (fr) Composés inhibiteurs de rip1, procédés de préparation et d'utilisation associés
MA30906B1 (fr) Composes et compositions en tant quinhibiteurs des proteines kinases
MA33419B1 (fr) Composés et compositions pour le traitement de maladies parasitaires
MA41179A (fr) Composés inhibiteurs de parg
MA47447A (fr) 2-hétéroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides pour le traitement du cancer
MA40523A (fr) 2-(morpholin-4-yl)-1,7-naphthyridines
MA33488B1 (fr) Motifs de modification chimique pour des inhibiteurs et mimétiques de miarn
MA64509B1 (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA64121B1 (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA34308B1 (fr) Triazolopyridines substituées
MA29141B1 (fr) Pyrrolopyrazoles, servant de puissants inhibiteurs de kinases
MA38380A1 (fr) Inhibiteurs quinazoline de l'activation des formes mutantes du récepteur de croissance épidermique (egfr)
MA35422B1 (fr) Imidazopyridazines amino-substituees
MA29378B1 (fr) Composition pharmaceutique comprenant une diphenyluree substituee par un omega-carboxyaryle pour le traitement du cancer
MA30784B1 (fr) Derives phenyliques et utilisation de ceux-ci en tant qu'immunomodulateurs.
MA41135B1 (fr) Benzamides substitués 1,3-thiazol-2-yl
MA32684B1 (fr) Dérivés de picolinamide en tant qu'inhibiteurs de kinase
MA35187B1 (fr) Composés ayant une activité antagoniste d'un récepteur muscarinique et agoniste d'un récepteur béta2 adrénergique
MA38391A1 (fr) Dérivés de pyridinyl et triazolone pyridinyl de fusion
MA41434A (fr) 7-benzyl-4-(4-(trifluorométhyl)benzyl)-1,2,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(4h)-one, ses sels et leur utilisation en thérapie
MA30325B1 (fr) Composes qui potentialisent le recepteur ampa et leurs utilisations en medecine
MA30343B1 (fr) Composition immunogene
MA30629B1 (fr) Derives de pyrazole servant d'inhibiteurs du cytochrome p450
MA31919B1 (fr) Composés inhibiteurs de la dipeptidyl peptidase-iv, leurs procédés de préparation, et compositions pharmaceutiques contenant ces composés comme agent actif
MA34331B1 (fr) Composés pyrazole comme inhibiteurs du récepteur sigma